Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology
Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology GlobeNewswire December 03, 2025 Phase 3 trial assessed the efficacy and safety of Elevar's rivoceranib in combination with camrelizumab as a first-line therapy for uHCC The combination continued to show clinically meaningful survival improvement versus sorafenib, a standard first-line treatment for uHCC […]